These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35780235)

  • 21. Treatment with Atorvastatin During Vascular Remodeling Promotes Pericyte-Mediated Blood-Brain Barrier Maturation Following Ischemic Stroke.
    Yang Y; Yang LY; Salayandia VM; Thompson JF; Torbey M; Yang Y
    Transl Stroke Res; 2021 Oct; 12(5):905-922. PubMed ID: 33423214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone Fracture Pre-Ischemic Stroke Exacerbates Ischemic Cerebral Injury in Mice.
    Wang L; Kang S; Zou D; Zhan L; Li Z; Zhu W; Su H
    PLoS One; 2016; 11(4):e0153835. PubMed ID: 27089041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-149-5p regulates blood-brain barrier permeability after transient middle cerebral artery occlusion in rats by targeting S1PR2 of pericytes.
    Wan Y; Jin HJ; Zhu YY; Fang Z; Mao L; He Q; Xia YP; Li M; Li Y; Chen X; Hu B
    FASEB J; 2018 Jun; 32(6):3133-3148. PubMed ID: 29401609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
    Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
    Sayour AA; Celeng C; Oláh A; Ruppert M; Merkely B; Radovits T
    Diabetologia; 2021 Apr; 64(4):737-748. PubMed ID: 33483761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis.
    Shah GN; Price TO; Banks WA; Morofuji Y; Kovac A; Ercal N; Sorenson CM; Shin ES; Sheibani N
    J Pharmacol Exp Ther; 2013 Mar; 344(3):637-45. PubMed ID: 23249625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIM2 deletion enhances blood-brain barrier integrity in experimental ischemic stroke.
    Xu SY; Bian HJ; Shu S; Xia SN; Gu Y; Zhang MJ; Xu Y; Cao X
    CNS Neurosci Ther; 2021 Oct; 27(10):1224-1237. PubMed ID: 34156153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
    Bailey CJ; Day C; Bellary S
    Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
    Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy.
    Bessho R; Takiyama Y; Takiyama T; Kitsunai H; Takeda Y; Sakagami H; Ota T
    Sci Rep; 2019 Oct; 9(1):14754. PubMed ID: 31611596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy.
    Bhardwaj G; Vakani M; Srivastava A; Patel D; Pappachan A; Murumkar P; Shah H; Shah R; Gupta S
    Arch Biochem Biophys; 2021 Oct; 710():108995. PubMed ID: 34289381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans.
    Nakachi S; Okamoto S; Tamaki K; Nomura I; Tomihama M; Nishi Y; Fukushima T; Tanaka Y; Morishima S; Imamura M; Maeda S; Tsutsui M; Matsushita M; Masuzaki H
    Biomed Pharmacother; 2022 May; 149():112864. PubMed ID: 35367765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
    Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
    Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.